Intercell AG has appointed Staph Leavenworth Bakali as its chief business officer with responsibility for all commercial aspects of the company including sales and marketing, corporate and business development and alliance management.
Mr Bakali has been a member of the company’s supervisory board for nearly five years, but recently stepped down from this position to join the management board. Mr Bakali was previously chief executive officer of Genocea Biosciences Inc of Cambridge, Massachusetts and before that, chief operating officer at ID Biomedical of Canada and PowderJect of the UK, which were acquired respectively by GlaxoSmithKline Plc and Chiron Corp, now part of Novartis.
Copyright 2010 Evernow Publishing Ltd